Sign up to save your data!
Some tips to help get started:
Processing...
There are 397 active trials for advanced/metastatic other solid tumor. Click on a trial to see more information. Note that this list also includes some trials that are only for specific cancer types like lung cancer. To see trials customized to a patient, please select a patient above.
397 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial evaluates the safety and dosage of RMC-6291 and RMC-6236, investigational drugs targeting KRAS G12C-mutant proteins, in adults with advanced or metastatic KRAS G12C-mutant solid tumors, including those with NSCLC.
ClinicalTrials.gov ID: NCT06128551
HealthScout AI summary: This trial evaluates feasibility of therapeutic drug monitoring-based dosing of atezolizumab, a PD-L1 immune checkpoint inhibitor, in patients 18 and older with locally advanced or metastatic cancer, aiming to maintain efficacy while potentially reducing drug exposure. Eligible participants must have an ECOG performance status of 0 to 2 and adequate organ function.
ClinicalTrials.gov ID: NCT06066138
HealthScout AI summary: This trial evaluates a personalized multi-peptide neo-antigen vaccine combined with poly ICLC and the PD-1 inhibitor nivolumab in adult patients with advanced, treatment-resistant stage IIIC-IV melanoma, hormone receptor positive HER2-negative metastatic breast cancer, and stage III-IV non-small cell lung cancer, focusing on safety and immune response.
ClinicalTrials.gov ID: NCT05098210
HealthScout AI summary: This trial investigates BBI-355, a CHK1 inhibitor targeting replication stress in oncogene-amplified tumors, as monotherapy and in combination with erlotinib or futibatinib in patients with advanced solid tumors that have progressed after standard treatments.
ClinicalTrials.gov ID: NCT05827614
HealthScout AI summary: This trial involves adults with unresectable locally advanced or metastatic NSCLC harboring active EGFR mutations, including C797S, who have progressed on osimertinib or another third-generation EGFR-TKI, receiving the investigational fourth-generation EGFR tyrosine kinase inhibitor H002 to assess its safety and preliminary anti-tumor activity.
ClinicalTrials.gov ID: NCT05519293
HealthScout AI summary: This trial evaluates ABSK112, a small molecule targeting EGFR exon 20 insertion mutations, in patients with locally advanced or metastatic non-small cell lung cancer characterized by these mutations, focusing on its safety, tolerability, and pharmacokinetics. The study involves dose escalation and an expansion cohort, enrolling adults with measurable disease and a life expectancy of at least three months.
ClinicalTrials.gov ID: NCT06225804
HealthScout AI summary: This trial evaluates APL-5125, an oral CK2α pathway and Wnt signaling inhibitor, in adults with advanced solid tumors, focusing particularly on colorectal carcinoma, who have no remaining standard treatment options.
ClinicalTrials.gov ID: NCT06399757
HealthScout AI summary: This trial enrolls adult patients with advanced or metastatic solid tumors, particularly those with CCNE1 amplification, who have progressed after standard treatments. It investigates NKT3964, a novel oral CDK2 degrader using a PROTAC mechanism, in a first-in-human open-label study to evaluate safety and preliminary anti-tumor activity.
ClinicalTrials.gov ID: NCT06586957
HealthScout AI summary: The trial is enrolling adults with advanced solid tumors, including triple-negative breast cancer and melanoma, to evaluate the investigational drug STX-001, an intratumoral self-replicating mRNA therapy encoding IL-12, as monotherapy or combined with PD-1 inhibitor pembrolizumab, focusing on tumors resistant to standard immune checkpoint therapies.
ClinicalTrials.gov ID: NCT06249048
HealthScout AI summary: The trial involves patients who are postmenopausal women with relapsed locally advanced or metastatic AR+/HER2-/ER+ breast cancer, focusing on the safety and efficacy of EP0062 (vosilasarm), a selective androgen receptor modulator. Participants must have previously treated, inactive cancer and meet specific cardiac and medication criteria.
ClinicalTrials.gov ID: NCT05573126
